Advances in spinal muscular atrophy therapeutics.

abstract：:The treatment of stroke caused by intracranial vessel occlusion with intravenous recombinant tissue plasminogen activator (rt-PA) was the only evidence-based treatment option for a long time. Nevertheless the response rate was disappointing in large vessel occlusions. Five studies that evaluated the efficacy of mechan...

journal_title：Therapeutic advances in neurological disorders

authors： Fischer S,Weber W

更新日期：2017-11-22 00:00:00

abstract：OBJECTIVE:Intracranial aneurysms (IAs) require deliberately selected treatment strategies as they are incrementally found prior to rupture and deleterious subarachnoid haemorrhage (SAH). Multiple and recurrent aneurysms necessitate both neurointerventionalists and neurosurgeons to optimize aneurysmal occlusion in an in...

journal_title：Therapeutic advances in neurological disorders

authors： Mueller OM,Schlamann M,Mueller D,Sandalcioglu IE,Forsting M,Sure U

更新日期：2011-09-01 00:00:00

abstract：Background:The humanized anti-α4 integrin monoclonal antibody natalizumab has proven to be very effective in patients with highly active relapsing-remitting multiple sclerosis (MS), but harbors the risk of progressive multifocal leukoencephalopathy (PML). Recently, new therapeutic options have become available for pati...

journal_title：Therapeutic advances in neurological disorders

authors： Möhn N,Skripuletz T,Sühs KW,Menck S,Voß E,Stangel M

更新日期：2019-12-02 00:00:00

abstract：:Over 320 years after Thomas Sydenham described the condition labelled Sydenham's chorea, it remains poorly understood. The disorder is an antineuronal antibody-mediated neuropsychiatric disorder caused by a poststreptococcal, autoimmune condition affecting control of movement, mood, behaviour and potentially the heart...

journal_title：Therapeutic advances in neurological disorders

authors： Walker KG,Wilmshurst JM

更新日期：2010-09-01 00:00:00

abstract：:Experimental models of Parkinson's disease (PD) are of great importance for improving the design of future clinical trials. Various neurotoxic models are available, including 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), paraquat and rotenone. However, no model is considered perfect;...

journal_title：Therapeutic advances in neurological disorders

authors： Salama M,Arias-Carrión O

更新日期：2011-11-01 00:00:00

abstract：:Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that largely affects optic nerves and spinal cord. Recent studies have identified an elevation of serum anti-aquaporin 4 antibody as a hallmark of NMO. Typical cases of NMO significantly differ from multiple sclerosis (MS) in immunological markers, hi...

journal_title：Therapeutic advances in neurological disorders

authors： Okamoto T,Ogawa M,Lin Y,Murata M,Miyake S,Yamamura T

更新日期：2008-07-01 00:00:00

abstract：:Natalizumab is approved for the treatment of patients with relapsing-remitting multiple sclerosis who have failed first-line treatment with traditional disease-modifying therapies or who have highly active disease. The drug has proved highly effective, both in a clinical trial setting and in clinical practice, with ma...

journal_title：Therapeutic advances in neurological disorders

authors： Fernández O

更新日期：2013-03-01 00:00:00

abstract：:Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy has been considered a novel central nervous system autoimmune disease characterized by relapse and responsiveness to corticosteroid with a specific GFAP-Immunoglobulin G (IgG) being noted in cerebrospinal fluid. We report the case of a 21-year-old girl p...

journal_title：Therapeutic advances in neurological disorders

authors： Li XL,Han J,Zhao HT,Long YM,Zhang BW,Wang HY

更新日期：2020-06-03 00:00:00

abstract：:Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and dementia. Accumulating evidence suggests that inflammation is involved in the pathogenesis of AD. Epidemiological studies suggest that use of anti-inflammatory drugs is associated with a lower incidence of AD. However,...

journal_title：Therapeutic advances in neurological disorders

authors： Zhu M,Wang X,Sun L,Schultzberg M,Hjorth E

更新日期：2018-08-09 00:00:00

abstract：:The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-ß). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller proportion of patients develop NAbs. The principle in NAb in vitro assays...

journal_title：Therapeutic advances in neurological disorders

authors： Sorensen PS

更新日期：2008-09-01 00:00:00

abstract：Background:To compare the long-term clinical outcomes of different antihypertensive drugs in stable patients after acute hemorrhagic stroke (HS). Methods:From January 2001 to December 2013, patients with first-ever primary HS were identified in the National Health Insurance Research Database, Taiwan. Patients with tra...

journal_title：Therapeutic advances in neurological disorders

authors： Liu CH,Lin YS,Chi CC,Liou CW,Lee JD,Peng TI,Lee TH

更新日期：2018-09-28 00:00:00

abstract：:More than 30% of epilepsy patients remain refractory despite the advent of new antiepileptic drugs (AEDs) over two decades. Although a small percentage of these refractory patients may become seizure free when a new AED is added, combined administration of AEDs or the application of novel AEDs is the most common thera...

journal_title：Therapeutic advances in neurological disorders

authors： Chung SS

更新日期：2010-03-01 00:00:00

abstract：Background:Whole brain atrophy (WBA) estimates in multiple sclerosis (MS) correlate more robustly with clinical disability than traditional, lesion-based metrics. We compare Structural Image Evaluation using Normalisation of Atrophy (SIENA) with the icobrain longitudinal pipeline (icobrain long), for assessment of long...

journal_title：Therapeutic advances in neurological disorders

authors： Beadnall HN,Wang C,Van Hecke W,Ribbens A,Billiet T,Barnett MH

更新日期：2019-01-25 00:00:00

abstract：:Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that preven...

journal_title：Therapeutic advances in neurological disorders

authors： Castro-Borrero W,Graves D,Frohman TC,Flores AB,Hardeman P,Logan D,Orchard M,Greenberg B,Frohman EM

更新日期：2012-07-01 00:00:00

abstract：:Acute stroke is one of the major causes of death and disabilities. Since the 1980s many clinical studies have been conducted to evaluate neuroprotective approaches to treat this important brain vascular event. However, to date the only drug approved (recombinant tissue plasminogen activator [rtPA]) represents a thromb...

journal_title：Therapeutic advances in neurological disorders

authors： Subirós N,Del Barco DG,Coro-Antich RM

更新日期：2012-05-01 00:00:00

abstract：Background:Network science provides powerful access to essential organizational principles of the brain. The aim of this study was to investigate longitudinal evolution of gray matter networks in early relapsing-remitting MS (RRMS) compared with healthy controls (HCs) and contrast network dynamics with conventional atr...

journal_title：Therapeutic advances in neurological disorders

authors： Fleischer V,Koirala N,Droby A,Gracien RM,Deichmann R,Ziemann U,Meuth SG,Muthuraman M,Zipp F,Groppa S

更新日期：2019-04-24 00:00:00

abstract：:The World Wide Web is increasingly used in therapeutic settings. In this regard, internet-based interventions have proven effective in ameliorating several health behaviors, amongst them physical activity behavior. Internet-delivered interventions have shown positive effects on physical activity and physical function ...

journal_title：Therapeutic advances in neurological disorders

authors： Tallner A,Pfeifer K,Mäurer M

更新日期：2016-07-01 00:00:00

abstract：:Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA...

journal_title：Therapeutic advances in neurological disorders

authors： Escher CM,Paracka L,Dressler D,Kollewe K

更新日期：2017-02-01 00:00:00

abstract：:Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Demyelinization of nerve fibres not only affects the motor and sensory systems functionally, but may also cause psychopathological signs and symptoms. In addition to the psychiatric manifestations of MS, many patients have reacti...

journal_title：Therapeutic advances in neurological disorders

authors： Haussleiter IS,Brüne M,Juckel G

更新日期：2009-01-01 00:00:00

abstract：Background:Although the pathogenesis of myasthenia gravis (MG) is well known, prognostic markers are not yet available. We assessed the utility of anti-acetylcholine receptor (AChR) antibody (AChR-ab) titer and concentration of C3, C4, and C5a as potential severity biomarkers in MG. Methods:Levels of C3, C4, C5a, and ...

journal_title：Therapeutic advances in neurological disorders

authors： Aguirre F,Manin A,Fernandez VC,Justo ME,Leoni J,Paz ML,Villa AM

更新日期：2020-08-10 00:00:00

abstract：:Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three choline...

journal_title：Therapeutic advances in neurological disorders

authors： Yiannopoulou KG,Papageorgiou SG

更新日期：2013-01-01 00:00:00

abstract：:Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (...

journal_title：Therapeutic advances in neurological disorders

authors： Steinhoff BJ,Staack AM

更新日期：2019-09-09 00:00:00

abstract：:Brain imaging is increasingly used to support clinicians in diagnosing multiple sclerosis (MS) and monitoring its progression. However, the role of magnetic resonance imaging (MRI) in MS goes far beyond its clinical application. Indeed, advanced imaging techniques have helped to detect different components of MS patho...

journal_title：Therapeutic advances in neurological disorders

authors： Cortese R,Collorone S,Ciccarelli O,Toosy AT

更新日期：2019-06-27 00:00:00

abstract：:Stroke is the fifth leading cause of death and the most frequent cause of disability worldwide. Currently, stroke diagnosis is based on neuroimaging; therefore, the lack of a rapid tool to diagnose stroke is still a major concern. In addition, therapeutic approaches to combat ischemic stroke are still scarce, since th...

journal_title：Therapeutic advances in neurological disorders

authors： Ramiro L,Simats A,García-Berrocoso T,Montaner J

更新日期：2018-08-06 00:00:00

abstract：:The treatment of neuropathic pain is difficult. Oral pharmaceuticals have significant side effects, and treatment efficacy tends to be modest. The use of topical analgesics reduces the potential for systemic side effects and allows direct application of medications to the area of pain. The natural spicy substance, cap...

journal_title：Therapeutic advances in neurological disorders

authors： Peppin JF,Pappagallo M

更新日期：2014-01-01 00:00:00

abstract：:Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple sclerosis (MS), having been shown to produce a clinically meaningful improvement in walking ability in the subset of MS patients with Expanded Disability Status Scale 4-7. Recent responder subgroup analyses in the phase II...

journal_title：Therapeutic advances in neurological disorders

authors： Albrecht P,Bjørnå IK,Brassat D,Farrell R,Feys P,Hobart J,Hupperts R,Linnebank M,Magdič J,Oreja-Guevara C,Pozzilli C,Salgado AV,Ziemssen T

更新日期：2018-10-05 00:00:00

abstract：Background:Lennox-Gastaut syndrome (LGS) is a typical intractable form of epilepsy that most often occurs between the second and sixth year of life. This study aimed to evaluate the clinical efficacy and safety of ketogenic diet therapies (DTs) for LGS with mitochondrial dysfunction. Methods:This was a retrospective s...

journal_title：Therapeutic advances in neurological disorders

authors： Na JH,Kim HD,Lee YM

更新日期：2020-02-06 00:00:00

abstract：:Topiramate has been widely utilized worldwide as an effective medication against partial- and generalized-onset seizures. Extended-release topiramate was developed to provide patients with the convenience of once-daily dosing and potentially improved tolerability by reducing serum concentration fluctuation. USL255 is ...

journal_title：Therapeutic advances in neurological disorders

authors： Chung SS

更新日期：2015-05-01 00:00:00

abstract：:For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone. Treating aggressive forms...

journal_title：Therapeutic advances in neurological disorders

authors： Awad A,Stüve O

更新日期：2009-11-01 00:00:00

abstract：BACKGROUND:Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). Peginterferon beta1a is an interferon conjugated with a polyethylene glycol (PEG) moiety. Pegylation increases a drug's half life and exposure, and may also reduce immunogen...

journal_title：Therapeutic advances in neurological disorders

authors： White JT,Newsome SD,Kieseier BC,Bermel RA,Cui Y,Seddighzadeh A,Hung S,Crossman M,Subramanyam M

更新日期：2016-07-01 00:00:00